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For skull base meningiomas, several treatment paradigms are available: Observation with serial imaging, surgical
resection, stereotactic radiosurgery, radiation therapy or some combination of both. The choice depends on several
factors. In this review we evaluate different treatment options, the outcome of modern irradiation techniques as
well as the clinical results available, and establish recommendations for the treatment of patients with skull-base
meningiomas.Introduction
There is controversy regarding the optimal treatment of
patients with benign tumors of the skull base such as
meningiomas. Different analyses focus on local control,
morbidity and mortality of treatment, treatment dur-
ation and recovery times, as well as quality of life
(QOL).
Skull base anatomy is intricate, and the close proxim-
ity of tumors to vital organs at risk (OAR) influence
treatment decisions. Moreover, treatment recommenda-
tions depend on the experience of the surgeon or radi-
ation oncologist, on available technology, and, last but
not least, on the patients’ goals and preferences. In gen-
eral, especially in the case of symptomatic lesions, treat-
ment is mandatory for these usually benign tumors.
However, in the case of an incidental finding or if clin-
ical symptoms are mild and precise imaging
characterization and definition can be obtained, observa-
tion may be chosen. This is particularly important in the
elderly. In younger patients, observed patients must be
followed closely because growth rates are variable.* Correspondence: Stephanie.Combs@med.uni-heidelberg.de
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reproduction in any medium, provided the orStudies show that annual growth rates are average,
1–3 mm per year. Such measurements do not reflect
tumor volume changes and do not reflect changes in
edema or continuing effects on brain tissue compression
[1,2]. During the observation period, it is essential to
keep patients in close follow-up, including contrast-
enhanced imaging and clinical-neurological assessment
including hearing evaluation, to minimize the risk of
neglecting rapid growth, or development of severe symp-
toms. In general there is no urgent need for immediate
surgical or radiotherapeutic intervention. However, when
tumor growth can be documented, when clinical symp-
toms develop or worsen, or in younger patients who
want to be treated at diagnosis, treatment may be
indicated.
Various surgical approaches are available, depending
on the size and location of the lesion, or on patient or
surgeon specific factors. Radiation based strategies have
become, in selected cases, a treatment alternative for
meningiomas, especially in recurrent or progressive
tumors with nonresectable remnants. This has improved
with the development of precise treatment techniques
such as radiosurgery (SRS) or fractionated stereotactic
radiotherapy (FSRT), Intensity Modulated Radiotherapy
(IMRT) or particle radiotherapy.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Combs et al. Radiation Oncology 2012, 7:226 Page 2 of 9
http://www.ro-journal.com/content/7/1/226To date, however, no formal randomized study com-
paring surgical resection with radiotherapy techniques
has been performed. Additionally, no study has pro-
spectively assessed patient-related outcome by patient
assessment and physician-based assessment, as well as
quality of QOL after treatment.
Meningioma resection has long been considered the
definitive treatment. Arguments for this approach in-
clude: Immediate removal of the lesion, rapid reduction
of intracranial mass effect, and possibility to perform a
precise pathological diagnosis. In general, radiation ther-
apy was reserved for malignant tumors or for recur-
rences. Development and improvement in radiation
therapy technology has altered this paradigm, and today,
treatment decisions are more individualized, depending
on the literature, physician’s preference and experience,
as well as patient related factors. In particular, the large
published experience using stereotactic radiosurgery
since 1987 has altered how many think about meningi-
omas. When only resection or observation were avail-
able, many smaller tumors were observed, even after
subtotal resection. This report provides a comprehensive
review of the literature enhanced by center-specific ex-
perience in different treatment modalities leading to
possible treatment algorithms for both indications.
Surgical resection
Today, microsurgical techniques and a precise preope-
rative imaging allow surgical procedures to be highly
effective with low procedure related morbidity [3].
Extensive, combined skull base approaches, although re-
fined over the past two decades, are less frequently used
nowadays since the paradigm of “preservation of func-
tion” has gained considerably more relevance [4,5].
Hence, the combination of more than one procedure
using different approaches, each with low surgical mor-
bidity, might be superior to one operation with disabling
morbidity. Reconstruction of the sagittal sinus after
“supramaximal” resection of falcine meningiomas involv-
ing this structure has been abandoned and replaced by
irradiation of (progressing) remnants. Endoscopic tech-
niques, either as a “stand alone” technique or as “endo-
scopic assisted microsurgery” have been introduced to
subsequently lower the morbidity related to the surgical
approach [6]. Altogether, the concept of functional pres-
ervation has led to a combination of surgical and radio-
therapeutic techniques within the framework of a
personalized therapy.
Radiosurgery and fractionated radiation therapy
Over the years, irradiation techniques have evolved from
conventional opposed field techniques, to 3D-conformal,
CT-based radiotherapy to even more conformal treat-
ments, such as fractionated stereotactic radiotherapy(FSRT) or single-fraction radiosurgery. The lattter techni-
ques offer highly precise dose application to defined target
volumes, with steep dose gradients to surrounding normal
tissue. The main difference between one time treatment
and fractionated regimens is based on biology: With radio-
surgery, the dose is applied in a single fraction. Single ses-
sion delivery has the potential for a greater tumoricidal
response. Safety is based on the most precise radiation
delivery using a stereotactic frame with judicious dose
selection. Fractionated treatments exploit intrinsic repair
mechanisms to reduce side effects to normal tissue. This
holds especially true for larger volumes: For radiosurgery, a
clear dose-volume-relationship has been shown, with risk
for treatment-related side effects increasing with treatment
volume [7]. On the other hand, a dose-dependent risk pro-
file has been reported, and, depending on size and location
of the lesion, generally marginal doses between 10–14 Gy
are used [8-10]. Today, radiosurgery is administered using
different techniques: Either dedicated devices such as the
Gamma Knife™ (GK) or robotic-based radiosurgery using
the Cyberknife-Technology™. Alternatively, stereotactically
guided treatments using linear accelerator (LINAC)-based
stereotactically based or frameless radiosurgery treatments
are available. From the clinical perspective in the case of
skull base meningiomas, all approaches have the potential
to create comparable dose distributions with respect to
dose conformity and sparing of normal tissue, therefore
leading to comparable short-term clinical outcomes [11-
13]. It is important to remember however that physicians
do not all use these techniques similarly. Different forms of
head/target fixation, different doses, different isodoses, dif-
ferent dose rates, different imaging-guidance techniques,
and different approaches to critical regional anatomy lead
to variability between centers.
Fractionated treatments are often applied as frac-
tionated stereotactic radiotherapy, or modern high-
precision image-guided radiotherapy (IGRT) approaches
allowing for significantly improved precision over older
radiotherapy paradigms. For complex shaped and larger
lesions, the development of Intensity Modulated Radio-
therapy (IMRT) offered another degree of freedom: As
such, treatments consist of a multifield techniques with
intensity modulated individual beams, improving dose
conformality especially to complex shapes in very close
vicinity to sensitive OAR.
Particle therapy is currently emerging since more and
more treatment facilities are becoming clinically active.
Its use in meningioma management is limited. With pro-
tons, reduction of integral dose to the patients can be
achieved due to the physical properties of the beam, an
inverted dose distribution with high local dose depos-
ition within the Bragg Peak. The depth of this peak is
energy dependent, leading to conformal dose distribu-
tions and reduction of entry and exit dose. However,
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ciated with the most conformal dose plans in clinical
use. Again, this is user and center dependent. Like all
elements of radiation techniques, this should be impro-
ved as treatment planning software works with device
hardware. With higher-LET particles, such carbon ions,
additionally biological properties can be exploited: Se-
vere radiation damage to the cell nuclei contribute to an
enhanced relative biological effectiveness (RBE). How-
ever, whether photons or protons are used, energy de-
position is determined by dose. For certain indications, a
clinical benefit of high-LET particles has been suggested,
and for high-risk meningiomas the rational has been
outlined and is currently being evaluated within a pro-
spective clinical trial [14]. Modern facilities use active
beam application, while older clinical data has been
obtained using passive beam delivery. Besides biology,
carbon ion beams are associated with less beam broad-
ening along the beam channel, resulting in slightly
improved dose conformality and sparing of OAR espe-
cially with deeper seated lesions. Figure 1 shows typical
dose distributions for photon IMRT, protons and carbon
ions for a patients with a skull base meningioma extend-
ing into the nasal cavity.
To conclusively report on clinical data of different ra-
diation techniques, we performed a literature search in
pubmed on the topic radiation therapy for the treatment
of skull base meningiomas with the following key words:
(meningioma OR skull base meningiomas OR (men-
ingiomas AND skull base)) AND (FSRT OR radiother-
apy OR radiosurgery OR radiation OR IMRT OR
proton) NOT case report NOT review. In total, 1237
citations were found.
We utilized the Cochrane Guidelines for the generation
of review articles (www.Cochrane.org/resources/handbook)Figure 1 Treatment planning comparison of Helical Tomotherapy IMR
(right).and chose only publications with a minimal patient num-
ber of 20 and a minimal follow-up time of 12 months to be
able to better ascertain tumor control rates and late effects
in addition to acute effects of treatment. Accordingly, case
reports, reviews or technical reports were not included into
this review.
Upon review, we excluded articles on optic nerve
sheath meningiomas (ONSM), as well as cervical or
non-skull-base intracranial meningiomas.
The techniques available in radiation oncology are
reflected in 38 publications on FSRT, 49 publications on
stereotactic radiosurgery, 68 publications on Gamma
Knife or Cyberknife radiosurgery, and 3 reports on IMRT.
For particle therapy, 10 articles could be found, predomin-
antly on proton radiotherapy. Certain high-volume centers
were identified for fractionated as well as radiosurgery
techniques, from which several of the publications were
derived. Two of the institutions with the most skull-base
meningioma patients are represented as co-authors of the
present review article.
Radiosurgery
Independent of technique, radiosurgery approaches are
comparable with respect to clinical outcome and tox-
icity. A clear volume-relationship for side effects has
been reported, as well as a clear dose-dependency; this
holds true for toxicity to cranial nerves, as well as for
the development of intracranial edema [8,15,16]. Based
on these data, limitations can be seen for complex
volumes adjacent to OAR and with increasing size, while
fractionated treatments are associated with a comparable
dose profile independent of tumor volume or diameter
[12,17-23]. This data obviously is based on the range of
tumor volumes selected for treatment. On the other
hand, for appropriate volumes, short term toxicity isT (left), scanned protons (middle) and scanned carbon ions
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times of radiosurgery, contributes to a high QOL as well
as the possibility of patients returning to work quickly
after treatment [24].
For radiosurgery, local control rates of 92-100% have
been reported. Toxicity to the cranial nerves are com-
monly kept below 5%, depending on clinical factors. Even
for meningiomas at the cerebello-pontine angle, facial
nerve morbidity is rare. In the past, higher rates of side
effects were observed, however, knowledge of normal-
tissue tolerance and distinct tolerance differences between
selected neural structures has been obtained. For example,
due to the tolerance of the optic pathway, maximum point
doses should be kept below 10 Gy (single fraction) to optic
pathway structures. Early reports which advocated a
<8 Gy approach, were likely too conservative. Older stud-
ies have shown that with 10–15 Gy, radiation induced
optic neuropathy was around 30%, and approximately
80% with doses of 15 Gy or more [25], while doses of 12–
16 Gy to only very small segments of the optic nerve were
associated with acceptable toxicity [8]. This is supported
by an extensive analysis by Mayo and colleagues, calculat-
ing a marked increase of risk at doses > 60 Gy at approxi-
mately 1.8 Gy/fraction and at >12 Gy for single-fraction
radiosurgery [10]. Other neural structures, such as other
cranial nerves, obviously tolerate slighty more dose [8].
Therefore, single dose prescription should aim at 12–
18 Gy marginal coverage, however, individual increase or
decrease in radiosurgical dose depends on tumor volume,
tumor histology, tumor location, neighboring OAR, dose
to OAR as well as individual pre-treatment factors such
as pre-existing neurologgic deficits and or previous
interventions.
The Pittsburgh group reported outcome in 168 patients
with petroclival meningioma treated with GK radiosurgery
[26]. Median dose to the tumor margin was 13 Gy; after
a median follow-up of 72 months, neurological status
improved in 44 patients (26%), remained stable in 98
(58%), and worsened in 26 (15%). Tumor volume de-
creased in 46% of the patients, and remained stable in
44%. Overall 5- and 10-year progression-free survival rates
were 91 and 86%. Tumor volume = 8 cm3 was significantly
associated with a higher risk of progression. Starke et al.
supported these results, with local control rates of 98%,
96%, and 78% at 3, 5, and 10 years [27]. 51% of the
patients showed decrease in tumor volume during follow-
up, and in 36% volume stability was was observed. Failure
was significantly associated with older age (> 65 years),
and lower margin dose (mostly associated with larger
treatment volumes). Of all, 91% of the patients demon-
strated no change or improvement in their neurological
condition.
A group of 251 patients were treated over a time span
of 22 years with Gamma Knife radiosurgery [15]; of these,tumor size decreased in 181 patients (72.1%) and was un-
changed in 67 patients (26.7%). The 3- and 10-year local
control rate was 99.4%; only 3 patients (1.2%) had in-field
tumor progression, and no marginal recurrences were
observed. The 1- and 5-year complication rates were 8.3%
and 11.5%, respectively. Radiation-related complications
were associated with convexity/falx tumors, not in the
skull base region, and increasing tumor volume on multi-
variate analysis.
Even for patients with brain stem compression or in
critical locations such as the foramen magnum, radiosur-
gery can be considered as a treatment alternative on an
individual decision basis, especially in older patients or
patients with significant comorbidities [28,29]; in gen-
eral, in these lesions, resection should be the first choice
if feasible, since tumors are often associated with symp-
toms alleviated with surgery, and risk for side effects is
considerably lower with more space between the tumor
and brain stem. However, for selected cases, radiosur-
gery can be applied safely when marginal doses are kept
below 15 Gy [9,30,31]. For example Nakaya et al. re-
ported 246 patients with brainstem compression from
benign skull-base tumors treated with Gamma Knife
radiosurgery [29]. A median marginal dose of 13 Gy was
prescribed. For meningiomas, median follow-up was
60 months. The tumor control rate was 100% for men-
ingiomas. Symptoms improved in 43.2% of patients with
meningioma.
Radiosurgery is a safe alternative for skull-base men-
ingioma, independent of location, however, limitations
must be kept in mind with close proximity to sensitive
OAR as well as with increasing volumes. Thus, a prefer-
ential indications are smaller volumes.
Fractionated stereotactic radiotherapy (FSRT)
Exploiting the radiobiological mechanisms of repair,
fractionated treatment with 1.8 – 2 Gy per fraction
offers the potential for a broader safety profile, especially
for tumors involving sensitive OAR, directly adjacent to
OAR, or with larger volumes. The benefit of fraction-
ation is comparable for smaller and larger lesions, there-
fore, dose and volume margins are more variable due to
a larger therapeutic window [32]. The special sensitivity
of OAR, such as the optic nerves or chiasm, often lead
to some compromise in dose prescription, potentially
jeopardizing local control. In such locations, therefore,
indications for radiosurgery versus fractionated treat-
ment should be weighed against each other [33,34].
Several techniques are used, from stereotactic regi-
mens, to image-guided highly precise approaches, with
comparable outcomes. Early data by Maire et al. demon-
strated neurological improvement in 72% patients with
skull base meningiomas treated with FSRT; progression-
free survival was 94%. Other studies with 24 to 72
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with median doses of 50 to 56.7 Gy, and rates for per-
manent deficits of 1.6% to 9.8%, depending on series
[19-21,35-40]. Most volumes were comparably large, be-
tween 14.5 and 57.2 ml. Minitti et al. could show that
even for large volumes up to 150 ml, the 3-year and 5-
year local control rates were 96% and 93% [22]. The Hei-
delberg group of 507 patients treated with either FSRT
or IMRT reported local control of 91% at 10 years for
benign meningiomas; QOL was unchanged in 47.7% of
the patients, and 37.5% showed improvement. Most
patients reported an improvement of symptoms or re-
main unchanged; in only a few patients disorders wor-
sened over time or side effects developed [18].
After radiation therapy volume reduction can be
observed over time: In 59 patients followed after FSRT,
the mean size reduction was 17%, 23%, and 30% (at <
24 months, 24–48 months, and 48–72 months); the mean
relative size reduction compared to the volume before
radiotherapy was 27% [41]. Similar results were observed
by Henzel et al., with a decrease in volume of 33% at
24 months and of 36% at 36 months after FSRT [20].
Assessment of neurocognitive functioning, which is of
concern in radiation treatment of benign lesions, has been
analyzed by independent groups: Steinvorth et al. per-
formed a neuropsychological evaluation in 40 patients
with skull base meningiomas [42]. Slight reduction in
memory functioning during treatment was observed, fol-
lowed by improvement in attention functions. No cogni-
tive deterioration during follow-up was shown, and mood
state improved after treatment. Nieuwenhuizen and co-
workers revealed impaired neurocognitive functioning in
meningioma patients after treatment, independent of sur-
gery or other treatment modalities. However, they could
show that additional radiation did not lead to a decline in
neurocognitive functioning or QOL [43]. An analysis of
self-reported outcome supported that most patients report
stable or increasing QOL and improvement of symptoms
during follow-up [18].
Intensity Modulated Radiotherapy (IMRT)
Treatment planning comparisons have shown the bene-
fits of IMRT compared to other 3D-treatments for sev-
eral indications. For meningiomas, this holds true
especially for larger volumes with complex anatomy
[13]. In terms of Planning Target Volume (PTV) cover-
age, there is an advantage in using IMRT for all target
shapes, but especially for irregularly shaped and and
concave volumes. In some cases, IMRT can reduce dose
to OAR, however, in total the volume of normal tissue
receiving a low dose can be larger than with FSRT [44].
Assuming comparable target coverage and dose, short-
term results after IMRT or FSRT are comparable [18]. A
benefit in terms of dose distribution for IMRT isespecially evident for highly complex anatomy, multiple
lesions or meningiomatosis [17]. Outcome after IMRT-
treated meningiomas is only available from a few institu-
tions: Early data from Heidelberg had shown excellent
local control of 94%, with improvement of preexisting
neurological deficits in 40% of the patients [45,46]; stable
disease was observed in 73.4%, and tumor volume re-
duction in 20.2% of the patients. Progression was evident
in 6.4% during follow-up. Long-term follow-up of the
same cohort of patients confirmed low rates of toxicity
and high local control, with improved or unchanged
QOL [18].
Thus, FSRT and IMRT provide excellent dose cover-
age, and choice of treatment should be made on an indi-
vidual basis depending on the anatomy. It should be
kept in mind that with FSRT integral dose might be
lower than with IMRT, which is of importance for long-
term outcomes especially in younger patients. Local con-
trol rates are high even for larger volume tumors, with
low rates of side effects. Therefore, fractionated techni-
ques offer excellent treatment options independent of
size and location of the lesion.
Particle therapy
Smaller series have been published on particle therapy,
mostly protons, for skull base meningiomas [47-54]: All
data compare well to photon series with FSRT, IMRT or
radiosurgery, with local control ranging between 88-100%
with low toxicity. As described above, protons are charac-
terized by an inverted dose profile leading to a potential
reduction of integral dose. Several studies and calculations
have shown that this could lead to a significant reduction
of long-term sequelae, such as neurocognitive dysfunc-
tioning or secondary malignancies. Only recently, Arvold
and colleagues compared proton with highly advanced
photon plans and suggested a 50% reduction of the risk
for radiation associated secondary malignancies; they also
suggested a, significant dose reduction to neurocognitive
and other critical structures [55]. This theoretical model
remains to be evaluated. On the other hand, no significant
difference in anticipated late effects as calculated by
NTCP models was determined, which was below 1% for
all modalities. To date, however, no controlled clinical trial
has been performed to confirm a benefit for skull base
tumors, and considering the required endpoints and long-
term horizon of follow-up this might be difficult to deter-
mine. When evaluating the dose distributions, perhaps
such trials are not required, especially when considering
that future proton treatment centers and devices are po-
tentially decreasing in cost and in the long-run resembling
modern photon radiotherapy in terms of cost. However,
to date, differences in cost and availibility drive such dis-
cussions and critical evaluation of data is necessary. It is
important to recall that a benign meningioma presents a
Figure 2 Multilocular relapse of a skull base meningioma 9 years after surgery in a 46-year old woman. 68-Ga-DOTATOC-PET (above) and
T1 weighted MRI (below). Red arrows show distant lesions initially detected by PET imaging.
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outside the imaging-defined target, is normal. Thus, with
any technique, an optimum goal is to deliver as little radi-
ation as possible to any structure outside the tumor. For
smaller volumes this is more readily achieved. With radio-
surgery, the most conformal and selective dose plans with
rigid target fixation, achieve this. With all approaches, this
goal is crucial. Although individual centers using different
techniques can advocate the value of the approach they
utilize from a physics perspective, only long-term clinical
outcomes of safety and efficacy are truly important.
Treatment planning for radiation therapy
Independent of technique and modality, exact target vol-
ume definition is an essential prerequisite for modern
highly precise and selective radiotherapy. For low-grade
meningiomas, it has been shown that location of local
recurrences is mainly outfield, i.e. commonly regions re-
ceiving less than 90% of the prescribed dose [56]. These
results support established dose concepts as described
above, and stress the necessity of reliable imaging-based
planning. For radiosurgery, smaller volume definition is
commonly performed, not including much of the dural
tail. With fractionated techniques, generally, regions of
the dural tail are included into the GTV, and therefore,
should be identified as meningioma and distinguished
from other reactive changes of the dura. Interestingly,
recurrence from the “dural tail” is uncommon. Biopsies
of dural tail tissue at resection tend to show hyperemic
dura and not tumor.
Meningiomas are best seen on MRI with contrast. For
selected basal tumors, fat suppression imaging is helpful.
CT or PET can be adjuncts in selected cases, For bony
structures, i.e. infiltration of cavernous sinus or other
regions of the skull base, CT imaging can best show infil-
tration and osteolytic areas of bony infiltration. Additional
information is provided by contrast-enhanced MRI, espe-
cially on T1-weighted imaging, best for delineation of
macroscopically visible meningiomas. Combined or fusedMR-CT may assist in tumor delineation especially when
the bony base of the skull obscures the target in CT
images [57].
Especially in regions of infiltration into musculature such
as pterygoid region, of along dural pathways, it is often dif-
ficult to define exact borders. Additional imaging such as
amino-acid-PET or somatostatin-receptor-PET may help
distinguish tumor from inflammation and edema.
A study on [11]C-methionine positron emission tomog-
raphy (MET-PET) for gross tumor volume delineation in
fractionated stereotactic radiotherapy of skull base men-
ingiomas demonstrated that addition of MET-PET can
lead to an increase, as well as a decrease in Gross Target
Volume (GTV) [58]. Additionally, the same group could
show that inter-observer variability or target volume
definition was reduced significantly when adding MET-
PET to CT-MRI-based contouring; with additional PET-
information the target volumes were almost identical,
while prominent differences in volumes was seen without
PET-information [59]. Besides amino acid PET, [(68)Ga]-
DOTA-D Phe[1]-Tyr[3]-Octreotide (DOTATOC)-PET
can be used for treatment planning of meningiomas
(Figure 2). Within a group of 26 patients receiving 68-Ga-
DOTATOC-PET/CT for radiation treatment planning
additional information on tumor extension was seen in
17/26 patients; moreover, median GTV was significantly
larger after integration of PET, on case-by-case basis how-
ever enlargements, as well as reduction of GTV and CTV
volumes were seen [60]. Most adaptations were seen in
the postoperative setting, or in regions of bony anatomy.
Graf et al. confirmed the influence of 68-Ga-DOTATOC-
PET in 54 lesions, mostly showing an increase in GTV
with PET-imaging [61]. In the Heidelberg and Munich
center, 68-Ga-DOTATOC-PET is standard-of-care for
treatment planning of meningiomas based on the initial
implementation of the tracer in this patient population.
Besides volume optimization, 68-Ga-DOTATOC-PET can
help in detection of meningiomas, especially smaller
lesions or lesions in direct vicinity of bony structures.
Figure 3 Treatment algorithm for skull base meningiomas modified from Combs SE et al. Radiother Oncol 2012 [18].
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Based on the clinical data provided above, the indication
both for surgical resection as well as radiation therapy
or radiosurgery is based on individual factors, such as
patient age and comorbidities, the presence of clinical
symptoms, volume and affected anatomical areas, mass
effect of the lesion or compression of OAR, known
growth rate, as well as the patient’s preference.
Patients with aymptomatic lesions with typical imaging
of a benign skull base meningioma can be offered a
wait-and-scan program including thorough regular
clinical-neurological and opthalmological assessment, as
well as contrast-enhanced MR-imaging. However if a
tumor is optimal for irradiation now, and subsequent
growth would eliminate this option, then irradiation may
be a good choice now for that patient. For typical cranial
base meningiomas, low kinetics of growth or expansion
have been observed, and they can appear as indolent
lesions over long time spans [2]. Some, however, grow
more rapidly. On the other hand, if the lesion is resect-
able, a neurosurgical intervention can be performed, if
the patient prefers immediate treatment. Early radiation
therapy can be discussed, however, in asymptomatic
patients the minimal residual risk for side effects should
be weighed against arguments for early treatment. In
patients with clinical symptoms or observed significant
growth, therapy should be recommended:
In some lesions, both resection and radiosurgery can be
offered as equivalent treatment options in appropriately
selected patients, depending on the patient’s preference
and the technical availabilities. This holds especially true
for those lesions extending into critical regions such as
the cavernous sinus, where a complete resection would
only be possible with high rates of treatment-related side
effects. Here, radiotherapy/radiosurgery of the tumor
within the cavernous sinus is superior in terms of benefit/
risk ratio. While surgical resection offers the benefit ofsubsequent pathological evaluation of the specimen, ex-
cluding the remaining risk of 1-2% considered as “diag-
nostic miss” with imaging-based diagnosis. However, with
multimodal imaging including CT, MRI and PET this risk
remains to be below 5%, and with DOTATOC-PET im-
aging which is highly specific the risk is negligible.
For symptomatic patients with mass effect or OAR
compression, surgery should be performed; interdiscip-
linary discussion might decide on planned partial resec-
tions and subsequent wait-and-see or postoperative
radiation therapy to reduce mass effect but to reduce
treatment-related toxicity, such as with cavernous sinus
infiltration.
Controversy exists on early postoperative radiation ther-
apy versus a wait-and-see strategy postoperatively. Some
data can be used to argue for early treatment to improve
and prolong local control when compared to surgery alone,
supporting the idea that prolongation of local control can
be achieved especially after partial resection [35,62]. How-
ever, radiation performed as salvage-treatment after sur-
gery is comparably effective, and might be withheld to
minimize side effects and spare patients from additional
treatment that might not be necessary [18]. Ideally, at sur-
gery one hopes to resect the entire tumor. Alternatively,
combined resection followed by irradiation of any remnant,
provides a planned approach for the entire tumor, using
mechanical and biologic means.
In this regard histological evidence of atypical or anaplas-
tic meningioma (WHO II/III, =10% of all meningiomas)
offers different challenges. Knowledge of high-grade biol-
ogy changes the treatment paradigm compared to benign
lesions. This subgroup has tended to be more aggressive
and has been associated with a much poorer outcome
[63,64]. Thus, postoperative radiotherapy is rather recom-
mended for these patients. In contrast to minimized
stereotactic target volume approaches in benign meningi-
omas the PTV for atypical and anaplastic meningiomas is
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approx. 1–2 cm. Additionally, the benefit of postoperative
radiotherapy in this subgroup is related to greater radiation
doses of 60–66 Gy [65-68]. Interestingly, higher grade
meningiomas are rare at the skull base and are much more
common in convexity or parasagittal tumors.
In summary, several factors influence decision making
in benign-skull base meningiomas. The treatment algo-
rithm in Figure 3 outlines recommendations for coun-
celling patients and on selection of a possible treatment
regimen.
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